Expanding PML's functional repertoire through post-translational mechanisms

Frontiers in Bioscience

Volumn 14, Issue 6, 2009, Pages 2293-2306

  Nichol, Jessica N ^a   Petruccelli, Luca A ^a   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

ISG15; Phosphorylation; PML; PML RAR alpha; Post translational; Review; SUMO

Indexed keywords

NUCLEAR PROTEIN; PML PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; SUMO PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; REVIEW;

HUMANS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, RETINOIC ACID; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 63849264460     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3380     Document Type: Article

References (77)

1. M. N. Boddy, K. Howe, L. D. Etkin, E. Solomon and P. S. Freemont: PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene, 13(5), 971-82 (1996). (Pubitemid 26329084)
2. O. Kerscher, R. Felberbaum and M. Hochstrasser: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol, 22, 159-80 (2006).
3. J. M. Desterro, M. S. Rodriguez and R. T. Hay: SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell, 2(2), 233-9 (1998). (Pubitemid 128373648)
4. F. Melchior: SUMO-nonclassical ubiquitin. Annu Rev Cell Dev Biol, 16, 591-626 (2000).
5. D. Guo, M. Li, Y. Zhang, P. Yang, S. Eckenrode, D. Hopkins, W. Zheng, S. Purohit, R. H. Podolsky, A. Muir, J. Wang, Z. Dong, T. Brusko, M. Atkinson, P. Pozzilli, A. Zeidler, L. J. Raffel, C. O. Jacob, Y. Park, M. Serrano-Rios, M. T. Larrad, Z. Zhang, H. J. Garchon, J. F. Bach, J. I. Rotter, J. X. She and C. Y. Wang: A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet, 36(8), 837-41 (2004). (Pubitemid 39014100)
6. T. Kamitani, H. P. Nguyen, K. Kito, T. Fukuda-Kamitani and E. T. Yeh: Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem, 273(6), 3117-20 (1998). (Pubitemid 28109713)
7. T. Sternsdorf, K. Jensen and H. Will: Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol, 139(7), 1621-34 (1997). (Pubitemid 28079228)
8. S. Muller, M. J. Matunis and A. Dejean: Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. Embo J, 17(1), 61-70 (1998). (Pubitemid 28041048)
9. T. Kamitani, K. Kito, H. P. Nguyen, H. Wada, T. Fukuda-Kamitani and E. T. Yeh: Identification of three major sentrinization sites in PML. J Biol Chem, 273(41), 26675-82 (1998). (Pubitemid 28471682)
10. E. Duprez, A. J. Saurin, J. M. Desterro, V. Lallemand-Breitenbach, K. Howe, M. N. Boddy, E. Solomon, H. de Thé, R. T. Hay and P. S. Freemont: SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci, 112 (Pt 3), 381-93 (1999). (Pubitemid 29080660)
11. M. S. Rodriguez, C. Dargemont and R. T. Hay: SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem, 276(16), 12654-9 (2001) 0.
12. R. Geiss-Friedlander and F. Melchior: Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8(12), 947-56 (2007). (Pubitemid 350176509)
13. V. Bernier-Villamor, D. A. Sampson, M. J. Matunis and C. D. Lima: Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell, 108(3), 345-56 (2002). (Pubitemid 34178399)
14. M. H. Tatham, S. Kim, E. Jaffray, J. Song, Y. Chen and R. T. Hay: Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct Mol Biol, 12(1), 67-74 (2005). (Pubitemid 40082919)
15. O. Kirsh, J. S. Seeler, A. Pichler, A. Gast, S. Muller, E. Miska, M. Mathieu, A. Harel-Bellan, T. Kouzarides, F. Melchior and A. Dejean: The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J, 21(11), 2682-91 (2002). (Pubitemid 34619384)
16. A. Pichler, A. Gast, J. S. Seeler, A. Dejean and F. Melchior: The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell, 108(1), 109-20 (2002). (Pubitemid 34137016)
17. T. H. Shen, H. K. Lin, P. P. Scaglioni, T. M. Yung and P. P. Pandolfi: The mechanisms of PML-nuclear body formation. Mol Cell, 24(3), 331-9 (2006). (Pubitemid 44647906)
18. B. B. Quimby, V. Yong-Gonzalez, T. Anan, A. V. Strunnikov and M. Dasso: The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene, 25(21), 2999-3005 (2006). (Pubitemid 43780464)
19. L. Gong, S. Millas, G. G. Maul and E. T. Yeh: Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem, 275(5), 3355-9 (2000). (Pubitemid 30083039)
20. T. Nishida, F. Kaneko, M. Kitagawa and H. Yasuda: Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J Biol Chem, 276(42), 39060-6 (2001).
21. T. Nishida, H. Tanaka and H. Yasuda: A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur J Biochem, 267(21), 6423-7 (2000).
22. L. Gong and E. T. Yeh: Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem, 281(23), 15869-77 (2006). (Pubitemid 43848478)
23. K. I. Kim, S. H. Baek, Y. J. Jeon, S. Nishimori, T. Suzuki, S. Uchida, N. Shimbara, H. Saitoh, K. Tanaka and C. H. Chung: A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs. J Biol Chem, 275(19), 14102-6 (2000). (Pubitemid 30339685)
24. Y. Itahana, E. T. Yeh and Y. Zhang: Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol, 26(12), 4675-89 (2006). (Pubitemid 43877584)
25. H. Zhang, H. Saitoh and M. J. Matunis: Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol, 22(18), 6498-508 (2002).
26. A. M. Ishov, A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss, 3rd and G. G. Maul: PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol, 147(2), 221-34 (1999).
27. H. Li, C. Leo, J. Zhu, X. Wu, J. O'Neil, E. J. Park and J. D. Chen: Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol, 20(5), 1784-96 (2000). (Pubitemid 30100196)
28. S. Zhong, S. Muller, S. Ronchetti, P. S. Freemont, A. Dejean and P. P. Pandolfi: Role of SUMO-1-modified PML in nuclear body formation. Blood, 95(9), 2748-52 (2000).
29. M. S. Jang, S. W. Ryu and E. Kim: Modification of Daxx by small ubiquitin-related modifier-1. Biochem Biophys Res Commun, 295(2), 495-500 (2002). (Pubitemid 34785862)
30. K. Nacerddine, F. Lehembre, M. Bhaumik, J. Artus, M. Cohen-Tannoudji, C. Babinet, P. P. Pandolfi and A. Dejean: The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell, 9(6), 769-79 (2005). (Pubitemid 41724105)
31. J. L. Best, S. Ganiatsas, S. Agarwal, A. Changou, P. Salomoni, O. Shirihai, P. B. Meluh, P. P. Pandolfi and L. I. Zon: SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell, 10(4), 843-55 (2002). (Pubitemid 35335639)
32. C. Fu, K. Ahmed, H. Ding, X. Ding, J. Lan, Z. Yang, Y. Miao, Y. Zhu, Y. Shi, J. Zhu, H. Huang and X. Yao: Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene, 24(35), 5401-13 (2005). (Pubitemid 43080084)
33. N. Cohen, M. Sharma, A. Kentsis, J. M. Perez, S. Strudwick and K. L. Borden: PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J, 20(16), 4547-59 (2001). (Pubitemid 32772048)
34. T. Sternsdorf, K. Jensen, B. Reich and H. Will: The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem, 274(18), 12555-66 (1999).
35. F. M. Boisvert, M. J. Hendzel and D. P. Bazett-Jones: Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol, 148(2), 283-92 (2000). (Pubitemid 30078240)
36. F. Lehembre, S. Muller, P. P. Pandolfi and A. Dejean: Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene, 20(1), 1-9 (2001). (Pubitemid 32142332)
37. A. Chalkiadaki and I. Talianidis: SUMO-dependent compartmentalization in promyelocytic leukemia protein nuclear bodies prevents the access of LRH-1 to chromatin. Mol Cell Biol, 25(12), 5095-105 (2005). (Pubitemid 40781109)
38. M. K. Chelbi-Alix, L. Pelicano, F. Quignon, M. H. Koken, L. Venturini, M. Stadler, J. Pavlovic, L. Degos and H. de Thé: Induction of the PML protein by interferons in normal and APL cells. Leukemia, 9(12), 2027-33 (1995). (Pubitemid 26023786)
39. C. Lavau, A. Marchio, M. Fagioli, J. Jansen, B. Falini, P. Lebon, F. Grosveld, P. P. Pandolfi, P. G. Pelicci and A. Dejean: The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene, 11(5), 871-6 (1995).
40. R. D. Everett and M. K. Chelbi-Alix: PML and PML nuclear bodies: implications in antiviral defence. Biochimie, 89(6-7), 819-30 (2007). (Pubitemid 47008945)
41. G. G. Maul, H. H. Guldner and J. G. Spivack: Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol, 74 (Pt 12), 2679-90 (1993). (Pubitemid 24020661)
42. J. H. Ahn and G. S. Hayward: The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J Virol, 71(6), 4599-613 (1997). (Pubitemid 27204153)
43. R. D. Everett and G. G. Maul: HSV-1 IE protein Vmw110 causes redistribution of PML. Embo J, 13(21), 5062-9 (1994). (Pubitemid 24341087)
44. S. Muller and A. Dejean: Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol, 73(6), 5137-43 (1999). (Pubitemid 29246776)
45. G. G. Maul and R. D. Everett: The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J Gen Virol, 75 (Pt 6), 1223-33 (1994). (Pubitemid 24174037)
46. C. Boutell, A. Orr and R. D. Everett: PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J Virol, 77(16), 8686-94 (2003). (Pubitemid 36936079)
47. M. H. Tatham, M. C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E. G. Jaffray, J. J. Palvimo and R. T. Hay: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol, 10(5), 538-46 (2008). (Pubitemid 351627373)
48. J. H. Ahn, E. J. Brignole, 3rd and G. S. Hayward: Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING fingerdependent cryptic transactivator function of PML. Mol Cell Biol, 18(8), 4899-913 (1998). (Pubitemid 28343073)
49. H. Kang, E. T. Kim, H. R. Lee, J. J. Park, Y. Y. Go, C. Y. Choi and J. H. Ahn: Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J Gen Virol, 87(Pt 8), 2181-90 (2006). (Pubitemid 44178096)
50. A. L. Adamson and S. Kenney: Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol, 75(5), 2388-99 (2001). (Pubitemid 32147577)
51. G. Dellaire, R. W. Ching, H. Dehghani, Y. Ren and D. P. Bazett-Jones: The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci, 119(Pt 6), 1026-33 (2006).
52. R. D. Everett, P. Lomonte, T. Sternsdorf, R. van Driel and A. Orr: Cell cycle regulation of PML modification and ND10 composition. J Cell Sci, 112 (Pt 24), 4581-8 (1999). (Pubitemid 30034807)
53. G. Dellaire, C. H. Eskiw, H. Dehghani, R. W. Ching and D. P. Bazett-Jones: Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci, 119(Pt 6), 1034-42 (2006).
54. B. Terris, V. Baldin, S. Dubois, C. Degott, J. F. Flejou, D. Henin and A. Dejean: PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res, 55(7), 1590-7 (1995).
55. C. Gurrieri, P. Capodieci, R. Bernardi, P. P. Scaglioni, K. Nafa, L. J. Rush, D. A. Verbel, C. Cordon-Cardo and P. P. Pandolfi: Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst, 96(4), 269-79 (2004). (Pubitemid 38256272)
56. J. Bloom and M. Pagano: Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol, 13(1), 41-7 (2003). (Pubitemid 36269179)
57. P. P. Scaglioni, T. M. Yung, L. F. Cai, H. Erdjument-Bromage, A. J. Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst and P. P. Pandolfi: A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell, 126(2), 269-83 (2006). (Pubitemid 44092959)
58. Z. G. Wang, D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi and P. P. Pandolfi: PML is essential for multiple apoptotic pathways. Nat Genet, 20(3), 266-72 (1998). (Pubitemid 28507671)
59. S. Yang, C. Kuo, J. E. Bisi and M. K. Kim: PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol, 4(11), 865-70 (2002). (Pubitemid 35331361)
60. R. Bernardi, P. P. Scaglioni, S. Bergmann, H. F. Horn, K. H. Vousden and P. P. Pandolfi: PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol, 6(7), 665-72 (2004). (Pubitemid 38960925)
61. T. Jenuwein and C. D. Allis: Translating the histone code. Science, 293(5532), 1074-80 (2001). (Pubitemid 32758077)
62. V. Lallemand-Breitenbach, J. Zhu, F. Puvion, M. Koken, N. Honore, A. Doubeikovsky, E. Duprez, P. P. Pandolfi, E. Puvion, P. Freemont and H. de Thé: Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med, 193(12), 1361-71 (2001). (Pubitemid 32565965)
63. F. Hayakawa and M. L. Privalsky: Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell, 5(4), 389-401 (2004). (Pubitemid 38482074)
64. T. Hunter: The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell, 28(5), 730-8 (2007). (Pubitemid 350217067)
65. M. Pampin, Y. Simonin, B. Blondel, Y. Percherancier and M. K. Chelbi-Alix: Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol, 80(17), 8582-92 (2006). (Pubitemid 44384869)
66. W. Yuan and R. M. Krug: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J, 20(3), 362-71 (2001). (Pubitemid 32126972)
67. K. Kok, A. van den Berg, P. M. Veldhuis, A. Y. van der Veen, M. Franke, E. F. Schoenmakers, M. M. Hulsbeek, A. H. van der Hout, L. de Leij, W. van de Ven and et al.: A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res, 54(15), 4183-7 (1994). (Pubitemid 24258128)
68. I. Pitha-Rowe, W. J. Petty, Q. Feng, P. H. Koza-Taylor, D. A. Dimattia, L. Pinder, K. H. Dragnev, N. Memoli, V. Memoli, T. Turi, J. Beebe, S. Kitareewan and E. Dmitrovsky: Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res, 64(21), 8109-15 (2004). (Pubitemid 39446950)
69. J. B. Andersen and B. A. Hassel: The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev, 17(6), 411-21 (2006). (Pubitemid 44793124)
70. S. Kitareewan, I. Pitha-Rowe, D. Sekula, C. H. Lowrey, M. J. Nemeth, T. R. Golub, S. J. Freemantle and E. Dmitrovsky: UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 99(6), 3806-11 (2002). (Pubitemid 34252187)
71. S. J. Shah, S. Blumen, I. Pitha-Rowe, S. Kitareewan, S. J. Freemantle, Q. Feng and E. Dmitrovsky: UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther, 7(4), 905-14 (2008). (Pubitemid 351551044)
72. M. P. Malakhov, K. I. Kim, O. A. Malakhova, B. S. Jacobs, E. C. Borden and D. E. Zhang: High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem, 278(19), 16608-13 (2003). (Pubitemid 36799523)
73. D. C. Schwartz and M. Hochstrasser: A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci, 28(6), 321-8 (2003). (Pubitemid 36776295)
74. T. Sternsdorf, E. Puccetti, K. Jensen, D. Hoelzer, H. Will, O. G. Ottmann and M. Ruthardt: PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol, 19(7), 5170-8 (1999). (Pubitemid 29289555)
75. Y. E. Kim, D. Y. Kim, J. M. Lee, S. T. Kim, T. H. Han and J. H. Ahn: Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for localization, sumoylation, and inhibition of monocyte differentiation. Biochem Biophys Res Commun, 330(3), 746-54 (2005).
76. J. Zhu, J. Zhou, L. Peres, F. Riaucoux, N. Honore, S. Kogan and H. de Thé: A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 7(2), 143-53 (2005). (Pubitemid 40248340)
77. F. Hayakawa, A. Abe, I. Kitabayahi, P. P. Pandolfi and T. Naoe: Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem, Epub ahead of print (2008).